Naghdi, Seyran
Underwood, Martin
Madan, Jason
Brown, Anna
Duncan, Callum
Matharu, Manjit
Aksentyte, Aiva
Davies, Natasha
Rees, Sophie
Cooklin, Andrew
Grove, Amy
Mistry, Hema http://orcid.org/0000-0002-5023-1160
Funding for this research was provided by:
Health Technology Assessment Programme (NIHR132803, NIHR132803, NIHR132803, NIHR132803, NIHR132803, NIHR132803, NIHR132803, NIHR132803, NIHR132803)
Article History
Received: 12 October 2023
Accepted: 20 November 2023
First Online: 6 December 2023
Declarations
:
: Not required.
: Martin Underwood is chief investigator or co-investigator on multiple previous and current research grants from the UK National Institute for Health Research and is a co-investigator on grants funded by the Australian NHMRC and Norwegian MRC. He was an NIHR Senior Investigator until March 2021. He is a director and shareholder of Clinvivo Ltd, which provides electronic data collection for health services research. He is part of an academic partnership with Serco Ltd, funded by the European Social Fund, related to return-to-work initiatives. He receives some salary support from University Hospitals Coventry and Warwickshire. He is a co-investigator on two current and one completed NIHR-funded studies that have, or have had, additional support from Stryker Ltd.Amy Grove is a member of the NIHR HTA Commissioning Committee and a member of the NIHR DSE Fellowship Funding Committee.Callum Duncan is chair of Scottish Intercollegiate Guideline Network (SIGN) 155 and has provided advice on the use of Botox, CGRP monoclonal antibodies and CGRP antagonists to the Scottish Medicines Consortium and on Eptinezumab to NICE. He was the Secretary for the British Association for the Study of Headache 2015–2022 and is a Board member of Anglo Dutch Migraine Association.Manjit Matharu is the President of the medical advisory board of the CSF Leak Association. He has received consulting fees from AbbVie, TEVA, Lundbeck, Eli Lilly, Salvia, and Pfizer. He has received payment for the development of educational presentations from AbbVie, Pfizer and Eli Lilly and support for attending a meeting from Pfizer. He is on the advisory board for AbbVie, TEVA, Lunbeck, Eli Lilly, Salvia and Pfizer. He has the following patent issued WO2018051103A1: System and method for diagnosing and treating headaches. He has stock options with Tesla, Adobe, Nvidia, META, and Microsoft. He has received grants from Abbott, Medtronic and Ehlers Danlos society.Hema Mistry is a member of the NIHR HTA General Funding Commissioning Committee.